Tissue factor pathway inhibitor activity in patients with IDDM.

Leurs, P B; van Oerle, R; Hamulyak, K; Wolffenbuttel, B H

Leurs, P B; van Oerle, R; Hamulyak, K; Wolffenbuttel, B H.

Affiliation

Leurs PB; Department of Internal Medicine, University Hospital, Maastricht, The Netherlands.

Diabetes ; 44(1): 80-4, 1995 Jan.

Article in En | MEDLINE | ID: mdl-7813818

Subject(s)

Diabetes Mellitus, Type 1/physiopathology; Fibrinolytic Agents/pharmacology; Lipoproteins/physiology; Adult; Diabetes Mellitus, Type 1/metabolism; Endothelium, Vascular/drug effects; Endothelium, Vascular/metabolism; Endothelium, Vascular/physiopathology; Female; Fibrinolytic Agents/metabolism; Glucose/administration & dosage; Glucose/pharmacology; Heparin/administration & dosage; Heparin/pharmacology; Humans; Hyperglycemia/metabolism; Hyperglycemia/physiopathology; Injections, Intravenous; Lipoproteins/blood; Lipoproteins/metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1/blood; Tissue Plasminogen Activator/blood; von Willebrand Factor/analysis

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Fibrinolytic Agents / Lipoproteins Type of study: Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Year: 1995 Type: Article Affiliation country: Netherlands

Search on Google

XML

PubMed Links